Fidelity Emerging Markets has published its monthly factsheet for August 2025. The Trust reported positive returns, outperforming its benchmark, with stock selection in Brazil, Taiwan and China adding value...
Elementis announced that CFO Ralph Hewins will retire at the end of 2025 after nine years with the company. He will be succeeded by Kath Kearney-Croft, who joins as CFO designate on 3 November 2025 before taking up the role on 1 January 2026...
Manx Financial Group’s profits are surging, Payment Assist is flying, and a new high-margin fintech overdraft product is about to launch. Group FD James Smeed reveals how the company’s 2025 strategy is reshaping its lending engine and unlocking new revenue streams...
Pharma congresses draw crowds, but Talking Medicines is shifting focus to the harder measure of success, whether messages truly resonate with healthcare professionals...
Andrew Hume, CEO of Thor Energy reflects on how the global clean energy transition is reshaping opportunities for investors and business graduates alike, highlighting the strategic roles needed to navigate capital, risk and innovation...
Fidelity European Trust highlighted strong contributions in August 2025 from KBC Groupe, which upgraded full year guidance, and Novo Nordisk, which advanced on positive trial results and regulatory approval for Wegovy...
August kept markets steady on the surface but revealed diverging signals in policy, earnings, and sector performance that will shape investor positioning...
Real Estate Credit Investments has extended its share buyback programme to 31 March 2026 with a limit of up to £10 million. Since the launch of its first programme in 2023, the Company has repurchased over 7.6 million shares for £9.4 million...
Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
Boku reported strong interim results for the six months to 30 June 2025, with revenue up 34% to $63.3 million and adjusted EBITDA rising 53% to $21.8 million. Digital Wallets and Account-to-Account revenue nearly doubled, while group cash increased to $192 million...
Fidelity Emerging Markets has published its monthly factsheet for August 2025. The Trust reported positive returns, outperforming its benchmark, with stock selection in Brazil, Taiwan and China adding value...
Elementis announced that CFO Ralph Hewins will retire at the end of 2025 after nine years with the company. He will be succeeded by Kath Kearney-Croft, who joins as CFO designate on 3 November 2025 before taking up the role on 1 January 2026...
Manx Financial Group’s profits are surging, Payment Assist is flying, and a new high-margin fintech overdraft product is about to launch. Group FD James Smeed reveals how the company’s 2025 strategy is reshaping its lending engine and unlocking new revenue streams...
Pharma congresses draw crowds, but Talking Medicines is shifting focus to the harder measure of success, whether messages truly resonate with healthcare professionals...
Andrew Hume, CEO of Thor Energy reflects on how the global clean energy transition is reshaping opportunities for investors and business graduates alike, highlighting the strategic roles needed to navigate capital, risk and innovation...
Fidelity European Trust highlighted strong contributions in August 2025 from KBC Groupe, which upgraded full year guidance, and Novo Nordisk, which advanced on positive trial results and regulatory approval for Wegovy...
August kept markets steady on the surface but revealed diverging signals in policy, earnings, and sector performance that will shape investor positioning...
Real Estate Credit Investments has extended its share buyback programme to 31 March 2026 with a limit of up to £10 million. Since the launch of its first programme in 2023, the Company has repurchased over 7.6 million shares for £9.4 million...
Cizzle Biotechnology is now in commercial motion, with its lung cancer diagnostic test entering clinical validation across North America. Backed by Cizzle Bio, OmniHealth, and the Moffitt Cancer Center, the company is moving from lab bench to nationwide rollout — with royalty payments already in hand...
Boku reported strong interim results for the six months to 30 June 2025, with revenue up 34% to $63.3 million and adjusted EBITDA rising 53% to $21.8 million. Digital Wallets and Account-to-Account revenue nearly doubled, while group cash increased to $192 million...
